 |
|
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(4):909-923. Published online 2023 May 25 DOI: https://doi.org/10.3350/cmh.2023.0114
|
|
Citations to this article as recorded by
 The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma
Beom Kyung Kim
Gut and Liver.2024; 18(1): 3. CrossRef Hepatocellular Carcinoma: Advances in Systemic Therapy
Insija Ilyas Selene, Merve Ozen, Reema A. Patel
Seminars in Interventional Radiology.2024; 41(01): 056. CrossRef Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis
YiFeng Liang, LiMing Gan, DeJin Zeng, LangHua Lin, ZheKun Xiong, FangLian Liao, ALing Wang
Clinical and Translational Oncology.2024;[Epub] CrossRef Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells
Zengbin Wang, Linqing Wu, Yu Zhou, Zhong Chen, Tao Zhang, Hong Wei, Zhihong Wang
Frontiers in Pharmacology.2024;[Epub] CrossRef Current progress of pig models for liver cancer research
Luyao Wang, Yuexian Piao, Fucheng Guo, Jiarui Wei, Yurong Chen, Xiangpeng Dai, Xiaoling Zhang
Biomedicine & Pharmacotherapy.2023; 165: 115256. CrossRef
|